THE ARISING · Longevity & Healthspan
INmune Bio Tests Quantum Computing and AI to Find New Uses for Alzheimer's Drug
A biotech company wants a quantum computer to tell it what else its Alzheimer's drug might treat. So far, nothing has been found. What exists is a plan, and a plan that includes a test of whether the quantum part helps at all.
INmune Bio, a Florida company, has announced a collaboration with Quantum Computing Inc. (QCi), a New Jersey company that builds quantum machines powered by light. According to Longevity.Technology, the machine is QCi's Dirac-3S. The drug is XPro, also called XPro1595, an investigational Alzheimer's treatment.
Most drug development starts with a disease and looks for a molecule. This project starts with the molecule. XPro is designed to block soluble tumor necrosis factor, or TNF, a protein involved in inflammation. The idea, as the source describes it, is to quiet damaging inflammatory signaling while leaving alone other TNF jobs the immune system relies on.
The companies will combine quantum computing, AI and conventional analytics. They will draw on INmune Bio's preclinical data, data from four clinical trials, and public biomedical datasets. The aim is to find diseases driven by the same biology XPro targets, then rank them by how likely a trial is to succeed.
CEO David Moss said the team will look for diseases "whose human biology matches what we've already seen XPro do." He said they will start with rare diseases, where trials can be smaller, faster and more capital-efficient. Qualifying pediatric approvals may also earn a Priority Review Voucher, a regulatory incentive linked to faster review of a future application.
What does the quantum machine do? QCi describes the Dirac-3S as an entropy quantum optimization machine. Optimization means finding the best choice when there are too many combinations to check one by one. Matching diseases, patient groups and biomarkers may be that kind of problem. QCi says the machine runs at room temperature and low power, without the specialized cooling many quantum approaches need.
The most useful detail for judging the claims is the control. The companies plan to run the same analysis with conventional statistical and machine-learning methods and compare the results. That will show whether quantum optimization adds anything. If standard tools reach the same answers, that will be visible too.
The evidence level here is very early. The source describes a Stage 1 engagement, with options for more work, and QCi's first commercial customer in pharmaceuticals and biotech. The language is about what the companies intend to do. No findings have been reported. A computer-ranked list of candidate diseases would still be a set of hypotheses. It would not show that XPro works for any of them.
For brain aging, the relevance is indirect. Inflammation runs through many agerelated illnesses, and researchers sometimes call the slow, low-grade version "inflammaging." Longevity Technology notes that a drug dialing down one inflammatory protein might, in theory, reach beyond the brain. That is the source's framing of a possibility, not a result.
XPro's Alzheimer's path is moving separately. According to the company, as reported by Longevity.Technology, it has been granted FDA Fast Track designation and reached regulatory alignment at an End-of-Phase 2 meeting. It says it is positioned for an integrated Phase 2b/3 program in early Alzheimer's with neuroinflammation. Those are company statements, and XPro remains investigational.
What to watch next
Whether the companies publish the comparison between the quantum and conventional methods, and whether any disease picked by the analysis moves into actual testing.